TLX-83

N/A

Report date: 2025/03/11 17:00:26
NME

Base Information

Drug NameTLX-83
Drug Alias NameTLX-83TLX83
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 1 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsCheckpoint kinase 1Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang UniversityShanghai Institute Of Materia Medica, Chinese Academy Of SciencesZhongshan Institute for Drug Discovery +[4] 
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesYantai New Drug Creation Shandong LaboratoryZhongshan Institute for Drug DiscoveryShanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A